Introduction
Conformational disorders such as Alzheimer's, Parkinson's, familial amyloidotic polyneuropathy and spongiform encephalopaties are a consequence of protein misfolding and aggregation predominantly in the form of amyloid ibrils. These pathologies represent a major health problem, which most probably will overwhelm the health systems of developed countries in the near future. Signi icant progress has been made recently to understanding the underlying mechanism of protein misfolding and aggregation. The current picture of protein aggregation is a phenomenon resulting from protein conformational luctuations leading to misfolded intermediates prone to form non-native interactions with other intermediates, resulting in amyloid ibril formation. Fortunately just a small group of proteins are associated with human conformational disorders. The primary causes that lead this group of proteins to misfolding and aggregation are point mutations, protein over-expression and failure of protein quality-control system. Beside amyloid formation, there are other types of aggregation available to a misfold-disease-related polypeptide chain in the proteinfree energy landscape. Among them, native-like aggregation is becoming a widely studied topic of research. This aggregation type, simultaneously straightforward and ubiquitous, seems to be involved concurrently in the pathway of amyloid ibril formation and disruption. In this review, the pathways of misfold and aggregation of a protein are accessed along with the primary causes that turn a native soluble protein into amyloid ibrils or native-like aggregate. In addition, an insight into the biophysical and biochemical aspects fundamental to amyloid ibril formation and nativelike aggregation is provided. Finally some clues are presented about what makes a protein follow an amyloidogenic or native-like aggregation pathway.
Conclusion
More laboratory data should be gathered about the structure, stability, dynamics and aggregation kinetics, in order to get a clearer picture of the biophysical mechanisms underlying native-like aggregation.
Introduction
Globular proteins rapidly fold into a well-de ined three-dimensional structure after synthesis in a cell endoplasmic reticulum (ER). However, under some conditions proteins do not fold correctly into their native structure. This malfunction might result in a set of maladies called protein conformational disorders or misfolding diseases 1 . These pathologies are called this due to the structural modi ications that can occur during the lifetime events of a protein. Amyloidoses are subset of misfolding diseases, comprising pathologies such as Alzheimer's, Parkinson's, familial amyloidotic polyneuropathy and spongiform encephalopaties, which result from misfolding of protein precursors and amyloid ibril formation.
One exquisite and contemporary way of describing the different threedimensional states accessible to a polypeptide chain is the protein-free energy landscape 2 . This has allowed scientists to grasp the protein folding, misfolding and aggregation mechanisms 3 . The features of a protein-free energy landscape depend mostly on the amino acid sequence, post-translational modi ications, ligands, cofactors and environmental conditions 4, 5 . After being synthesized a polypeptide chain usually folds into its native state, the lower free energy value of the landscape 2 ( Figure 1 ). However, under physiological conditions, a small group of peptides and proteins evolve into nonnative folds, partially or total unfolds and aggregates 6 . This can be seen as a modi ication in the shape of proteins free energy landscape ( Figure 2) .
The primary causes driving this reshaping are point mutations or protein over-expression 7 . Point mutations result in protein sequence modi ications favouring ibrillation by crowding protein partially unfolded states, which are prone to form aggregates 8, 9 . In that case, the protein free energy landscape is reshaped in such a way that it stabilizes protein-folding intermediates ( Figure 2) . Consequently, the increment on the concentration of intermediates can lead to aggregation. On the other hand, protein over-expression increases the concentration of polypeptide chains driving the polypeptide chain into an aggregation pathway as well. It is noteworthy that folding of a monomeric protein is a zeroorder reaction whereas aggregation is at least a irst-order reaction Licensee Beside mutation and protein overexpression, oxidative stress, activation of signalling pathways from quality control systems and post-translation modi ications may act as inductors of protein aggregation 11 . The accumulation of toxic aggregates might damage the cells and progress to intra-or extra-cellular amyloid deposits 1 . Recent studies with the amyloidogenic proteins β-2-microglobulin, insulin and stefin B have shown that native-like aggregation might be associated with conformational diseases [12] [13] [14] . Indeed, some authors suggest that amyloidogenesis under physiological conditions follows a native-like folding aggregation 12 , whereas others argue that it must follow a misfolding pathway 13, 14 . In spite of the lack of consensus about native-like aggregation, these investigations highlight the diversity of routes that might happen in conformational disorders. Despite this, it must be emphasized that native-like aggregates per se have been associated with cellular toxicity 15 . This meaningful research is opening new avenues into the understanding of non-amyloid aggregation types in human diseases. The aim of this review was to discuss what drives an amyloid protein precursor from an amyloidogenic to a native-like aggregation pathway.
Conformational disorders and amyloid ibril formation
From the tens of thousands of human proteins just 40 are currently known to be associated with amyloid formation. Amyloid ibrils are wellorganized protein aggregates that bind to congo red and thio lavin dyes. Morphologically, these ibrils have a variable length and a diameter between 6 and 12 nm, displaying a characteristic cross-β structure perpendicularly oriented to the ibber axis 16, 17 . The amyloid ibril lowresolution crystal structure shows a periodic β-sheet stacking stabilized by hydrogen bonds forming a packed zipper structure, the core of the ibre 18 . Along with morphological studies, the understanding of amyloid ibril formation kinetics is fundamental. Several models have been proposed to explain amyloid ibril formation kinetics. The classical kinetic view for amyloidogenesis describes amyloid ibril formation as a nucleation-dependent process with three distinct steps: (i) the lag phase, which is associated with the formation of the seed; (ii) the elongation phase, where the ibril growth takes place; and (iii) the inal steadystate phase 19 . The mechanism by which the nucleation process starts usually involves the native polypeptide precursor undergoing conformational changes that lead to the formation of a partially unfolded β-sheet-rich intermediate prior to aggregation and nucleus formation 20 . These conformational modi ications depend on the initial structural features of the native precursor. The elongation phase occurs through addition of monomeric units to the nuclei or stacking of small ibrils.
All major protein-fold motifs and protein hierarchical levels are represented in amyloid precursor proteins 6 . In this review oligomeric, monomeric and intrinsically unstructured proteins (IUP) amyloid precursor are discussed independently.
Oligomeric protein as amyloid precursors
Familial amyloidosis polyneuropathy (FAP), senile systemic amyloidosis (SSA) and amyotrophic lateral sclerosis (ALS) are conformational diseases involving multi-subunits of all-beta native-state precursors. In FAP and SSA the precursors are transthyretin variants and wildtype transthyretin (TTR) and in ALS the precursors are superoxide dismutase variants (SOD).
Human TTR is a homo-tetrameric protein with an eight-stranded β-sandwich motif in each subunit. Wilde-type TTR is associated with SSA, a degenerative disorder affecting predominantly individuals aged above 80 years. Variants of TTR are associated to FAP, an autosomic dominant degenerative disease. Depending on the TTR variant, the disease can have an earlier onset. In FAP, the physiological model for amyloid ibril formation establishes that amyloid formation by TTR is triggered by irreversible tetramer dissociation to a compact nonnative monomer. Depending on its thermodynamic stability, the nonnative monomer originates partially unfolded species with a high tendency for ordered aggregation into amyloid ibrils 8, 21, 22 . Interestingly, the amyloidogenic potential of TTR variants seems to correlate to their tendency to produce partially unfolded monomeric species 8 . There is very little knowledge regarding amyloid ibril formation from oligomeric proteins, and the few models found in the literature indicate that dissociation and thermodynamic instability of the resulting monomers are the primary causes behind the formation of amyloid ibrils ( Figure 3) .
Monomeric proteins as amyloid precursors
A group of monomeric proteins or its variants, such as lysozyme, cystatin C, immunoglobulin light chain, prolactin, insulin, lactoferrin and γ-crystallin, suffer conformational changes prior to amyloid ibril formation 23 . Human lysozyme is used as an example of monomeric amyloid protein precursor.
Human lysozyme is a small monomeric protein that belongs to the α+β motif with two structural domains, an alpha-domain with four alpha-helices and one 3 10 helix, and a beta domain, which consists mainly in an antiparallel β-sheet. Several lysozyme variants are associated with a familial non-neuropathic amyloidosis, which eventually forms amyloid deposits in the liver, spleen and kidneys 24, 25 . Comparative conformational stability studies between wild-type lysozyme and its amyloidogenic variants have shown that the native states of pathogenic variants are signi icantly less stable when compared to the wild-type protein 26 . Experimental data have shown that a lesser conformational stability of lysozyme variant correlates to a more amyloidogenic behaviour 27 . The suggested molecular mechanism of ibrillation of amyloidogenic variants of human lysozyme points to the native states in dynamic equilibrium with partially unfolded species. In turn, the partially unfolded intermediates of lysozyme can undergo self-association, leading to formation of β-sheet ordered aggregates and, eventually, amyloid ibrils 27 .
Native Tetramer of pathways for amyloid ibril formation from a homo-tetrameric protein precursor according to Quintas et al. 8 . The oligomeric protein in its native state dissociates into a nonnative monomer. The non-native monomeric species formed from dissociation may undergo several conformational changes due to a lack of conformational stability. As a result of hydrophobic exposition, these species may associate to form aggregates that eventually form amyloid ibrils.
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Intrinsically unfolded protein as amyloid precursors
After ribosomal synthesis, the folding pathway of globular proteins is overcome with a delicate balance between the hydrophobic effects, non-covalent interactions such as hydrogen bonds and con igurational entropy. The later is the negative counter-balance of forces involved in protein folding. However, IUP show a low overall hydrophobicity and a large net charge. Consequently, the major driving effect in the folding pathway is con igurational entropy, which may surpass the hydrophobic effect. This balance impels the polypeptide chain into a native disordered state 28 . Although the general underlying molecular mechanisms of amyloidogenesis for globular proteins are associated with protein misfolding, IUP must go through a partial folding in order to undergo aggregation and amyloid ibril formation 29 . The triggering cause for partial folding and amyloid ibril formation seems to be related to (i) natural propensity to form β-sheet intermediates; (ii) covalent modi ication, which may lead to the development of local structure; or (iii) protein overexpression, which may lead to aggregation simultaneously with β-sheet formation 30 . α-synuclein is an IUP associated with Parkinson's disease (PD), a movement disorder characterized by degeneration of dopaminergic neurons in the substantia nigra in the brain 31 . α-synuclein amyloid ibril formation seems to occur in the form of partially folded intermediate, pre-molten globule-like structure, the irst step for ibrillization 31 ( Figure 5 ). 13, 32, 33 . Unlike amyloidogenesis, native-like aggregation pathways do not present an unfolding specie to trigger oligomerization 33, 34 . In fact, native-like aggregation seems to proceed by stacking of near-native protein intermediates towards oligomeric species of inite size 32, 33 ( Figure 6 ). In humans, native-like aggregation has been described in a very small group of proteins. Among them β-2-microglobulin is associated with dialysis-related amyloidosis, factor VIII to haemophilia A, and insulin to insulin-injection amyloidosis 12, 13, 35 . One study with β-2-microglobin suggests that amyloid ibril formation occurs through self-assembly of native-like intermediates 12 . Pisal et al. showed that native-like aggregates of factor VIII are signi icantly more immunogenic than the nonaggregated monomeric form 36 . Oliveira et al. showed that post-folding modi ication of insulin with methylglyoxal inhibits formation and growth of insulin amyloid ibrils, blocking the seeding nuclei 13 . Interestingly, β-2-microglobulin is an all-beta motif protein whereas insulin is an all-alpha motif protein. This suggests that depending on the protein precursor fold class, native-like aggregation may proceed to amyloid-like ibrils.
Conformational disorders and native-like aggregation
A very interesting inding by Deva et al. show that native-like aggregation may inhibit ribosomal protein S6 from Thermus thermophilus to form amyloid. However, a very high protein concentration must be reached. According to the authors 33 , the off-pathway towards native-like aggregates overrules amyloid ibril formation at high protein concentration. It The association between nativelike aggregation and human disorders suggests that this is more relevant than was thought.
What drives an amyloidogenic protein into a native-like aggregation pathway?
Recent observations have shown that amyloid proteins, such as β-2-microglobulin, alpha-synuclein, insulin and ribosomal protein S6, can follow a native-like aggregation route 12, 13, 33, 37 . Some of these proteins when covalently modi ied or in very high protein concentration environment change from an amyloid ibril formation pathway to an native-like aggregation pathway 13, 33, 37 . The native-like aggregation pathway seems to compete with the amyloid ibril pathway.
Oliveira et al. have investigated the effects of methylglyoxal modi ication in insulin structure and ibril-forming properties. Circular dichroism studies showed that insulin glycation leads to native-like aggregation and that insulin ibril formation is substantially reduced. In effect, the authors suggest that glycation impairs insulin conformational alterations to the extent that they convert into an amyloidogenic intermediate, inhibiting the ibrillation process by blocking the formation of the seeding nuclei. Ultimately, ibril formation is reduced due to a lack of critical concentration of seeds 13 . Deva et al. has shown a similar result in different environmental conditions with ribosomal protein S6 33 . The authors state that when the concentration of ribosomal protein S6 is too high, the tendency is to form native-like aggregates instead of amyloid ibrils. According to the authors, amyloid ibrillation pathway demands a structural rearrangement of the monomeric specie into a pre-aggregation monomer before it starts to aggregate. This means there is a zero-order kinetics step before the aggregation into amyloid takes place in such a way that at very high concentration of protein, native-like aggregation, a pure irst-order step, is favoured 33 . Recently, a model for native-like aggregation of methylglyoxal-glycated proteins has been proposed 32 . Native-like aggregation occurs due to localized protein structural changes leading to a decrease on the conformational stability of the modi ied protein. Interestingly, the decrease in the stability of monomeric specie is counterbalanced by the formation of native-like aggregates that are thermodynamically more stable. The same study observed that the formation of glycated cytochrome c unfolded species is an off-pathway of the native-like aggregation route. The authors suggest that glycation of amyloidogenic proteins may lead to a shift from an amyloidogenic pathway to a native-like aggregation through a process that is thermodynamically and kinetically favoured 32 . Taking together the observations previously presented, what emerges is a preliminary picture of the driving forces that make an amyloidogenic protein follow a route of native-like aggregation. The irst step into the native-like aggregation route points to the inhibition of amyloidogenic intermediate formation. This may happen due to hindrance of amyloidogenic sequences to aggregate after post-folding modi ication of the protein precursor. The second step is the overcoming of protein freeenergy landscape barrier into nativelike aggregation. This might happen through a signi icant increment in protein concentration or by reducing the activation energy between nativestates and native-like aggregates. The second step can happen independently of the irst step.
Discussion
The authors have referenced some of their own studies in this review. The protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed.
Understanding how amyloidogenic proteins aggregate and form amyloid is a key issue in bringing light to understanding human conformational diseases and designing novel therapeutic approaches. Amyloid ibril formation usually occurs through one of the following events: (i) defective protein folding pathway and formation of misfolding intermediates, (ii) partial unfolding of the native state due to lack of protein stability, (iii) defective folding due to overcrowding of polypeptide chains in the endoplasmic reticulum and (iv) overwhelming of the cell-folding quality-control systems 8, 19, 38 . Overall, the underlying molecular mechanisms of aggregation into amyloid ibrils imply conformational changes of protein, disruption of native noncovalent interactions 35 and formation of aggregation-prone non-native intermediates 21 . Until recently amyloid ibril formation has been seen as a unique aggregation pathway in human conformational disorders. However, native-like aggregation may play a signi icant role in physiological processes. The biophysical mechanism underlying this process is not yet fully understood. However, the consensus is that native-like aggregation seems to proceed by stacking of near-native protein intermediates towards oligomeric species of inite size. In addition, experimental data suggest that the native-like aggregation pathway competes with the amyloid ibril pathway. Covalent modi ications such as glycation can prevent the formation of amyloidogenic intermediates, inhibiting the amyloidogenic pathway.
Conclusion
More laboratory data should be gathered about the structure, stability, dynamics and aggregation kinetics in Licensee Understanding what makes a protein follow an amyloid or a native-like aggregation pathway is essential to opening new avenues in therapeutic approaches to conformational diseases.
